Rel­ma­da to ex­plore psy­che­del­ic av­enue in pur­suit of de­pres­sion treat­ment; Ital­ian man­u­fac­tur­er joins NYSE

There has been a surge in in­vest­ment in psy­che­del­ic biotechs in re­cent years, and Rel­ma­da Ther­a­peu­tics is hop­ping on board.

CNS-fo­cused Rel­ma­da will pay a to­tal of $15 mil­lion up­front — a mix of cash and eq­ui­ty pur­chase — to grab rights to a new psilo­cy­bin and de­rivate pro­gram from Ar­bor­men­tis every­where ex­cept Asia. The goal will be to de­vel­op treat­ments for neu­ro­log­i­cal and psy­chi­atric dis­or­ders by com­bin­ing the as­sets with its own knowl­edge of neu­ro­plas­tic­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER